Delving into the Latest Updates on BOOST cells(Karolinska Institutet) with Synapse

Overview

Basic Info

Drug Type

Cell therapy

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Congenital DisordersSkin and Musculoskeletal DiseasesOther Diseases

Active Indication

Osteogenesis Imperfecta

Inactive Indication-

Originator Organization

Karolinska Institutet

Active Organization

Karolinska Institutet

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

An Exploratory, Open Label, Multiple Dose, Multicentre Phase I/II Trial Evaluating Safety and Efficacy of Postnatal or Prenatal and Postnatal Intravenous Administration of Allogeneic Expanded Fetal Mesenchymal Stem Cells for the Treatment of Severe Osteogenesis Imperfecta Compared With a Combination of Historical and Untreated Prospective Controls

An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe Osteogenesis Imperfecta compared with a combination of historical and untreated prospective controls.

Start Date12 Aug 2019

Sponsor / Collaborator

Karolinska Institutet

[+7]

NCT04623606

/ Unknown statusPhase 1/2IIT

Exploratory, Open Label, Multiple Dose, Phase I/II Trial Evaluating Safety, Efficacy of Intravenous and Intraosseous Infusion of Allogeneic Fetal Mesenchymal Stem In Treatment of Severe Osteogenesis Imperfecta Compared With Historical and Untreated Prospective Controls

An exploratory, open label, multiple dose, phase I/II trial (n=15) evaluating safety and efficacy of intravenous and intraosseous infusion of allogeneic expanded fetal mesenchymal stem cells (MSC) for the treatment of severe Osteogenesis Imperfecta (OI) compared with historical and untreated prospective controls.

Start Date20 May 2019

Sponsor / Collaborator